Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.45 below Organogenesis Holdings Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 396 other companies have achieved higher Quick Ratio than Organogenesis Holdings Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1865, from total ranking in the second quarter 2026 at 2557.

Explain Quick Ratio?
How much Cash & cash equivalents ORGO�s has?
What are ORGO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ORGO/financial-strength

https://api.csimarket.com/api/v1/companies/ORGO/fundamentals

https://api.csimarket.com/api/v1/companies/ORGO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ORGO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-47.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-66.54 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.45	Subscribe	Subscribe	Subscribe	Subscribe
ORGO's Total Ranking	# 1865	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-16.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-53.74 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 397
Healthcare Sector	# 752
Overall Market	# 2734

Quick Ratio Statistics
High	Average	Low
11.85	1.29	0
(Sep 30 2016)		(Sep 30 2018)

Financial Statements
Organogenesis Holdings Inc 's Current Liabilities	$ 48 Millions	Visit ORGO's Balance sheet
Organogenesis Holdings Inc 's Cash & cash equivalent	$ 21 Millions	Visit ORGO's Balance sheet
Source of ORGO's Sales		Visit ORGO's Sales by Geography

Cumulative Organogenesis Holdings Inc 's Quick Ratio

ORGO's Quick Ratio for the trailling 12 Months

ORGO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-6 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-33.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.9	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3969	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-13.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-14.38 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ORGO Financial Strength Comparisons >> Go to Compare ORGO Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ORGO's Current Liabilities to $47.65 millions, cumulative Quick Ratio to 0.9 below the ORGO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Organogenesis Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3154 to 3969.

Explain Quick Ratio?
How much Cash & cash equivalents ORGO�s has?
What are ORGO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 896
Within the Market	# 3969

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.45	0.9	0.03
(Jun 30 2025)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Nature s Sunshine Products inc	1.22	$ 89.377 Millions	$ 73.488 Millions
Ovid Therapeutics Inc	1.16	$ 13.811 Millions	$ 11.858 Millions
Filana Therapeutics Inc	1.12	$ 46.990 Millions	$ 41.946 Millions
Phathom Pharmaceuticals Inc	1.06	$ 184.558 Millions	$ 174.902 Millions
Eton Pharmaceuticals Inc	1.03	$ 55.628 Millions	$ 54.095 Millions
Akebia Therapeutics Inc	0.98	$ 159.254 Millions	$ 162.349 Millions
Acadia Pharmaceuticals Inc	0.97	$ 322.365 Millions	$ 332.217 Millions
Alkermes Plc	0.97	$ 631.314 Millions	$ 651.933 Millions
Geron Corporation	0.94	$ 69.794 Millions	$ 74.248 Millions
Mirum Pharmaceuticals Inc	0.86	$ 243.188 Millions	$ 283.080 Millions
Amphastar Pharmaceuticals Inc	0.86	$ 262.786 Millions	$ 306.303 Millions
Aclaris Therapeutics Inc	0.84	$ 20.394 Millions	$ 24.222 Millions
Seres Therapeutics Inc	0.84	$ 17.528 Millions	$ 20.893 Millions
Jazz Pharmaceuticals Plc	0.80	$ 2,036.400 Millions	$ 2,540.300 Millions
Zomedica Corp	0.80	$ 7.281 Millions	$ 9.096 Millions
Pfizer Inc	0.79	$ 25,140.000 Millions	$ 31,726.000 Millions
Xencor Inc	0.78	$ 59.622 Millions	$ 76.266 Millions
Janux Therapeutics Inc	0.77	$ 41.818 Millions	$ 54.247 Millions
Arcus Biosciences Inc	0.76	$ 151.000 Millions	$ 199.000 Millions
Ligand Pharmaceuticals Incorporated	0.75	$ 374.303 Millions	$ 500.569 Millions
Ionis Pharmaceuticals Inc	0.68	$ 296.303 Millions	$ 435.292 Millions
Liquidia Corporation	0.68	$ 396.091 Millions	$ 585.397 Millions
Bristol myers Squibb Company	0.67	$ 12,581.000 Millions	$ 18,753.000 Millions
Harrow Inc	0.66	$ 75.336 Millions	$ 114.224 Millions
Supernus Pharmaceuticals inc	0.62	$ 176.171 Millions	$ 285.397 Millions
Axsome Therapeutics Inc	0.62	$ 313.859 Millions	$ 509.719 Millions
Travere Therapeutics Inc	0.59	$ 123.542 Millions	$ 210.912 Millions
Clene Inc	0.58	$ 9.887 Millions	$ 17.114 Millions
Zoetis Inc	0.57	$ 1,533.000 Millions	$ 2,682.000 Millions
Organon and Co	0.55	$ 1,455.000 Millions	$ 2,652.000 Millions

Date modified: 2026-11-06T13:02:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.